Trial Profile
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Bimekizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms BE RADIANT
- Sponsors UCB Biopharma; UCB Pharma Inc
- 15 Nov 2023 Results comparing the efficacy of bimekizumab (BKZ) vs secukinumab (SEC) through 48 weeks (wks) for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis who had moderate to severe nail involvement at baseline, presented at the ACR Convergence 2023
- 15 Nov 2023 Results (n=654) assessing the efficacy of BKZ, as measured by complete or near complete skin clearance using the Psoriasis Area and Severity Index (PASI), over 144 weeks, and assess long-term safety of BKZ treatment presented at the ACR Convergence 2023
- 09 Oct 2023 According to an UCB media release, data from this study will be presented as oral presentation at at the 32nd European Academy of Dermatology and Venereology (EADV) Congress, October 11-14th in Berlin, Germany.